Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

Foundation Medicine, Takeda Collaborate to Develop CDx for NSCLC Therapies

Sep 18, 2020
|
staff reporter

NEW YORK – Foundation Medicine announced Friday its collaboration with Takeda Pharmaceuticals USA to develop Foundation's companion diagnostics for use with Takeda's lung cancer portfolio.

Financial and other terms of the deal were not disclosed. 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Keep It (Partly) Virtual

A survey by Nature finds that most researchers want scientific meetings to continue virtually or with a virtual component, even after the pandemic ends.

For Cross-Protection

Bloomberg reports that the B.1.351 SARS-CoV-2 viral variant could prompt the formulation of better vaccines.

Proteomics of Severity

Certain blood proteins may be able to distinguish COVID-19 patients who will become critically ill from those who will not, the Atlanta Journal-Constitution reports.

Genome Biology Papers on Regulatory Element, Single-Cell Integration, Sequence Simulation Tools

In Genome Biology this week: algorithm to assess regulatory features, approach to integrate multiple single-cell RNA-seq datasets, and more.

What's Popular?

In Business News

  1. Olink Files For Public Offering in US

  2. Twist Bioscience, Watchmaker Genomics Partner on High-Throughput NGS Applications

  3. Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience for up to $695M

  4. Quidel Stock Plunges in February as GenomeWeb Index Falls 3 Percent

  5. Quanterix Q4 Revenues Up 64 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.